{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T07:11:15Z","timestamp":1715411475270},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2013,5,29]],"date-time":"2013-05-29T00:00:00Z","timestamp":1369785600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s11926-013-0338-y","type":"journal-article","created":{"date-parts":[[2013,5,28]],"date-time":"2013-05-28T06:58:58Z","timestamp":1369724338000},"source":"Crossref","is-referenced-by-count":4,"title":["Tocilizumab in Pediatric Rheumatology: The Clinical Experience"],"prefix":"10.1007","volume":"15","author":[{"given":"Reut","family":"Gurion","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora G.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,5,29]]},"reference":[{"key":"338_CR1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/095952879708000106","volume":"80","author":"GF Still","year":"1897","unstructured":"Still GF. On a form of chronic joint disease in children. Med Chir Trans. 1897;80:47\u201360.","journal-title":"Med Chir Trans"},{"issue":"25","key":"338_CR2","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F Benedetti De","year":"2012","unstructured":"\u2022\u2022 De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385\u201395. doi: 10.1056\/NEJMoa1112802 . The 12\u00a0week double blind phase comparing response between tocilizumab and placebo showed that tocilizumab was effective in sJIA. This clinical trial completed the basis for FDA and EMEA labeling of tociluzimab as an effective agent in sJIA.","journal-title":"N Engl J Med"},{"issue":"25","key":"338_CR3","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396\u2013406. doi: 10.1056\/NEJMoa1205099 .","journal-title":"N Engl J Med"},{"issue":"6","key":"338_CR4","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.4049\/jimmunol.132.6.2948","volume":"132","author":"K Yoshizaki","year":"1984","unstructured":"Yoshizaki K, Nakagawa T, Fukunaga K, Tseng LT, Yamamura Y, Kishimoto T. Isolation and characterization of B cell differentiation factor (BCDF) secreted from a human B lymphoblastoid cell line. J Immunol. 1984;132(6):2948\u201354.","journal-title":"J Immunol"},{"issue":"2","key":"338_CR5","doi-asserted-by":"crossref","first-page":"412","DOI":"10.4049\/jimmunol.127.2.412","volume":"127","author":"A Muraguchi","year":"1981","unstructured":"Muraguchi A, Kishimoto T, Miki Y, Kuritani T, Kaieda T, Yoshizaki K, et al. T cell-replacing factor- (TRF) induced IgG secretion in a human B blastoid cell line and demonstration of acceptors for TRF. J Immunol. 1981;127(2):412\u20136.","journal-title":"J Immunol"},{"issue":"16","key":"338_CR6","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1073\/pnas.82.16.5490","volume":"82","author":"T Hirano","year":"1985","unstructured":"Hirano T, Taga T, Nakano N, Yasukawa K, Kashiwamura S, Shimizu K, et al. Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci U S A. 1985;82(16):5490\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"338_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V74.1.1.1","volume":"74","author":"T Kishimoto","year":"1989","unstructured":"Kishimoto T. The biology of interleukin-6. Blood. 1989;74(1):1\u201310.","journal-title":"Blood"},{"issue":"3","key":"338_CR8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1432-1033.1987.tb13452.x","volume":"168","author":"J Damme Van","year":"1987","unstructured":"Van Damme J, Cayphas S, Van Snick J, Conings R, Put W, Lenaerts JP, et al. Purification and characterization of human fibroblast-derived hybridoma growth factor identical to T-cell-derived B-cell stimulatory factor-2 (interleukin-6). Eur J Biochem. 1987;168(3):543\u201350.","journal-title":"Eur J Biochem"},{"issue":"5","key":"338_CR9","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/j.1460-2075.1987.tb02357.x","volume":"6","author":"P Poupart","year":"1987","unstructured":"Poupart P, Vandenabeele P, Cayphas S, Van Snick J, Haegeman G, Kruys V, et al. B cell growth modulating and differentiating activity of recombinant human 26-kd protein (BSF-2, HuIFN-beta 2, HPGF). EMBO J. 1987;6(5):1219\u201324.","journal-title":"EMBO J"},{"issue":"5143","key":"338_CR10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1126\/science.8272872","volume":"263","author":"C Lutticken","year":"1994","unstructured":"Lutticken C, Wegenka UM, Yuan J, Buschmann J, Schindler C, Ziemiecki A, et al. Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science. 1994;263(5143):89\u201392.","journal-title":"Science"},{"issue":"5143","key":"338_CR11","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1126\/science.8272873","volume":"263","author":"N Stahl","year":"1994","unstructured":"Stahl N, Boulton TG, Farruggella T, Ip NY, Davis S, Witthuhn BA, et al. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science. 1994;263(5143):92\u20135.","journal-title":"Science"},{"issue":"2","key":"338_CR12","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1006\/bbrc.1994.1525","volume":"200","author":"T Matsuda","year":"1994","unstructured":"Matsuda T, Yamanaka Y, Hirano T. Interleukin-6-induced tyrosine phosphorylation of multiple proteins in murine hematopoietic lineage cells. Biochem Biophys Res Commun. 1994;200(2):821\u20138. doi: 10.1006\/bbrc.1994.1525 .","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"338_CR13","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1006\/bbrc.1994.1970","volume":"202","author":"LC Berger","year":"1994","unstructured":"Berger LC, Hawley TS, Lust JA, Goldman SJ, Hawley RG. Tyrosine phosphorylation of JAK-TYK kinases in malignant plasma cell lines growth-stimulated by interleukins 6 and 11. Biochem Biophys Res Commun. 1994;202(1):596\u2013605. doi: 10.1006\/bbrc.1994.1970 .","journal-title":"Biochem Biophys Res Commun"},{"issue":"5206","key":"338_CR14","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.7701321","volume":"267","author":"X Zhang","year":"1995","unstructured":"Zhang X, Blenis J, Li HC, Schindler C, Chen-Kiang S. Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science. 1995;267(5206):1990\u20134.","journal-title":"Science"},{"issue":"3","key":"338_CR15","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/ar400","volume":"4","author":"T Naka","year":"2002","unstructured":"Naka T, Kishimoto T. Joint disease caused by defective gp130-mediated STAT signaling. Arthritis Res. 2002;4(3):154\u20136.","journal-title":"Arthritis Res"},{"issue":"7090","key":"338_CR16","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","volume":"441","author":"E Bettelli","year":"2006","unstructured":"Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441(7090):235\u20138. doi: 10.1038\/nature04753 .","journal-title":"Nature"},{"issue":"5","key":"338_CR17","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.4049\/jimmunol.141.5.1543","volume":"141","author":"M Okada","year":"1988","unstructured":"Okada M, Kitahara M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T. IL-6\/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol. 1988;141(5):1543\u20139.","journal-title":"J Immunol"},{"issue":"3","key":"338_CR18","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1042\/bj2650621","volume":"265","author":"PC Heinrich","year":"1990","unstructured":"Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990;265(3):621\u201336.","journal-title":"Biochem J"},{"issue":"1","key":"338_CR19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/jhep.2000.8532","volume":"32","author":"E Siewert","year":"2000","unstructured":"Siewert E, Bort R, Kluge R, Heinrich PC, Castell J, Jover R. Hepatic cytochrome P450 down-regulation during aseptic inflammation in the mouse is interleukin 6 dependent. Hepatology. 2000;32(1):49\u201355. doi: 10.1053\/jhep.2000.8532 .","journal-title":"Hepatology"},{"issue":"5","key":"338_CR20","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.semarthrit.2008.01.006","volume":"38","author":"DS Raj","year":"2009","unstructured":"Raj DS. Role of interleukin-6 in the anemia of chronic disease. Semin Arthritis Rheum. 2009;38(5):382\u20138. doi: 10.1016\/j.semarthrit.2008.01.006 .","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"338_CR21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00307733","volume":"13","author":"U Sack","year":"1993","unstructured":"Sack U, Kinne RW, Marx T, Heppt P, Bender S, Emmrich F. Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatol Int. 1993;13(2):45\u201351.","journal-title":"Rheumatol Int"},{"issue":"9","key":"338_CR22","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/art.1780340912","volume":"34","author":"F Benedetti De","year":"1991","unstructured":"De Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 1991;34(9):1158\u201363.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"338_CR23","first-page":"493","volume":"10","author":"F Benedetti De","year":"1992","unstructured":"De Benedetti F, Robbioni P, Massa M, Viola S, Albani S, Martini A. Serum interleukin-6 levels and joint involvement in polyarticular and pauciarticular juvenile chronic arthritis. Clin Exp Rheumatol. 1992;10(5):493\u20138.","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"338_CR24","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1002\/eji.1830181122","volume":"18","author":"T Hirano","year":"1988","unstructured":"Hirano T, Matsuda T, Turner M, Miyasaka N, Buchan G, Tang B, et al. Excessive production of interleukin 6\/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol. 1988;18(11):1797\u2013801. doi: 10.1002\/eji.1830181122 .","journal-title":"Eur J Immunol"},{"issue":"3","key":"338_CR25","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/art.1780330313","volume":"33","author":"M Jourdan","year":"1990","unstructured":"Jourdan M, Bataille R, Seguin J, Zhang XG, Chaptal PA, Klein B. Constitutive production of interleukin-6 and immunologic features in cardiac myxomas. Arthritis Rheum. 1990;33(3):398\u2013402.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"338_CR26","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1084\/jem.20020619","volume":"196","author":"T Atsumi","year":"2002","unstructured":"Atsumi T, Ishihara K, Kamimura D, Ikushima H, Ohtani T, Hirota S, et al. A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J Exp Med. 2002;196(7):979\u201390.","journal-title":"J Exp Med"},{"issue":"4","key":"338_CR27","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1084\/jem.187.4.461","volume":"187","author":"T Alonzi","year":"1998","unstructured":"Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G, et al. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med. 1998;187(4):461\u20138.","journal-title":"J Exp Med"},{"issue":"8","key":"338_CR28","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1002\/1529-0131(199908)42:8<1635::AID-ANR11>3.0.CO;2-Q","volume":"42","author":"M Sasai","year":"1999","unstructured":"Sasai M, Saeki Y, Ohshima S, Nishioka K, Mima T, Tanaka T, et al. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum. 1999;42(8):1635\u201343. doi: 10.1002\/1529-0131(199908)42:8<1635::AID-ANR11>3.0.CO;2-Q .","journal-title":"Arthritis Rheum"},{"issue":"1","key":"338_CR29","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/art.21537","volume":"54","author":"PK Wong","year":"2006","unstructured":"Wong PK, Quinn JM, Sims NA, van Nieuwenhuijze A, Campbell IK, Wicks IP. Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum. 2006;54(1):158\u201368. doi: 10.1002\/art.21537 .","journal-title":"Arthritis Rheum"},{"issue":"4","key":"338_CR30","first-page":"851","volume":"53","author":"K Sato","year":"1993","unstructured":"Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. 1993;53(4):851\u20136.","journal-title":"Cancer Res"},{"issue":"5","key":"338_CR31","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/00002281-200309000-00010","volume":"15","author":"S Yokota","year":"2003","unstructured":"Yokota S. Interleukin 6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis. Curr Opin Rheumatol. 2003;15(5):581\u20136.","journal-title":"Curr Opin Rheumatol"},{"issue":"9617","key":"338_CR32","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","volume":"371","author":"JS Smolen","year":"2008","unstructured":"Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987\u201397. doi: 10.1016\/S0140-6736(08)60453-5 .","journal-title":"Lancet"},{"issue":"3","key":"338_CR33","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/art.30158","volume":"63","author":"JM Kremer","year":"2011","unstructured":"Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011;63(3):609\u201321. doi: 10.1002\/art.30158 .","journal-title":"Arthritis Rheum"},{"issue":"1","key":"338_CR34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s10165-008-0125-1","volume":"19","author":"N Nishimoto","year":"2009","unstructured":"Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19(1):12\u20139. doi: 10.1007\/s10165-008-0125-1 .","journal-title":"Mod Rheumatol"},{"issue":"6","key":"338_CR35","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/art.20303","volume":"50","author":"N Nishimoto","year":"2004","unstructured":"Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50(6):1761\u20139. doi: 10.1002\/art.20303 .","journal-title":"Arthritis Rheum"},{"issue":"9","key":"338_CR36","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard.2006.068064","volume":"66","author":"N Nishimoto","year":"2007","unstructured":"Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66(9):1162\u20137. doi: 10.1136\/ard.2006.068064 .","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"338_CR37","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1136\/ard.2010.148700","volume":"71","author":"Y Yazici","year":"2012","unstructured":"Yazici Y, Curtis JR, Ince A, Baraf H, Malamet RL, Teng LL, et al. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis. 2012;71(2):198\u2013205. doi: 10.1136\/ard.2010.148700 .","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"338_CR38","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","volume":"58","author":"MC Genovese","year":"2008","unstructured":"Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58(10):2968\u201380. doi: 10.1002\/art.23940 .","journal-title":"Arthritis Rheum"},{"issue":"1","key":"338_CR39","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.2008.105197","volume":"69","author":"G Jones","year":"2010","unstructured":"Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88\u201396. doi: 10.1136\/ard.2008.105197 .","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"338_CR40","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","volume":"67","author":"P Emery","year":"2008","unstructured":"Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67(11):1516\u201323. doi: 10.1136\/ard.2008.092932 .","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"338_CR41","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/art.20944","volume":"52","author":"S Yokota","year":"2005","unstructured":"Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005;52(3):818\u201325. doi: 10.1002\/art.20944 .","journal-title":"Arthritis Rheum"},{"issue":"6","key":"338_CR42","doi-asserted-by":"crossref","first-page":"R1281","DOI":"10.1186\/ar1826","volume":"7","author":"P Woo","year":"2005","unstructured":"Woo P, Wilkinson N, Prieur AM, Southwood T, Leone V, Livermore P, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2005;7(6):R1281\u20138. doi: 10.1186\/ar1826 .","journal-title":"Arthritis Res Ther"},{"issue":"9617","key":"338_CR43","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","volume":"371","author":"S Yokota","year":"2008","unstructured":"Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371(9617):998\u20131006. doi: 10.1016\/S0140-6736(08)60454-7 .","journal-title":"Lancet"},{"issue":"9","key":"338_CR44","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/ard.2010.145359","volume":"70","author":"Y Inaba","year":"2011","unstructured":"Inaba Y, Ozawa R, Imagawa T, Mori M, Hara Y, Miyamae T, et al. Radiographic improvement of damaged large joints in children with systemic juvenile idiopathic arthritis following tocilizumab treatment. Ann Rheum Dis. 2011;70(9):1693\u20135. doi: 10.1136\/ard.2010.145359 .","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"338_CR45","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20460","volume":"63","author":"T Beukelman","year":"2011","unstructured":"\u2022\u2022 Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011;63(4):465\u201382. doi: 10.1002\/acr.20460 . These recommendations were formulated before FDA approval of tociluzimab for SJIA and hence do not evaluate the use of tociluzimab in sJIA.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"338_CR46","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/acr.21625","volume":"64","author":"EM DeWitt","year":"2012","unstructured":"\u2022\u2022 DeWitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S, et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2012;64(7):1001\u201310. doi: 10.1002\/acr.21625 . The 2012 consensus treatment plans which include biologics discusses the proceedings of how consensus plans for sJIA were developed including a tociluzimab pathway.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"338_CR47","unstructured":"\u2022 NCT01455701. A phase 1 pharmacokinetic and safety study of Tocilizumab (TCZ) in patients less than 2\u00a0years old with active Systemic Juvenile Idiopathic Arthritis (sJIA). http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01455701?term=NCT01455701&rank=1 . Accessed 2\/1\/13. This study which is ongoing and listed on the Clinical Trials.gov website will provide useful data about dosing if tociluzimab is used off label in those sJIA patients who are less than two years of age."},{"issue":"1","key":"338_CR48","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/acr.20319","volume":"63","author":"X Puechal","year":"2011","unstructured":"Puechal X, DeBandt M, Berthelot JM, Breban M, Dubost JJ, Fain O, et al. Tocilizumab in refractory adult still's disease. Arthritis Care Res (Hoboken). 2011;63(1):155\u20139. doi: 10.1002\/acr.20319 .","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10 (Supplement)","key":"338_CR49","first-page":"S83","volume":"64","author":"O El-Kayam","year":"2012","unstructured":"El-Kayam O, Jiries N, Dranitzki Z, Kivity S, Lidar M, Levy O, et al. Tocilizumab in adult Still's disease: the Israeli experience. Arthritis Rheum. 2012;64(10 (Supplement)):S83.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"338_CR50","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.cyto.2012.02.006","volume":"58","author":"M Shimizu","year":"2012","unstructured":"\u2022 Shimizu M, Nakagishi Y, Kasai K, Yamasaki Y, Miyoshi M, Takei S, et al. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. Cytokine. 2012;58(2):287\u201394. doi: 10.1016\/j.cyto.2012.02.006 . In this discussion the authors discuss whether tociluzimab effectively treats sub-clinical MAS and thus makes MAS more difficult to diagnose.","journal-title":"Cytokine"},{"issue":"6","key":"338_CR51","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/1759720X12455960","volume":"4","author":"S Yokota","year":"2012","unstructured":"Yokota S, Tanaka T, Kishimoto T. Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis. Ther Adv Musculoskelet Dis. 2012;4(6):387\u201397. doi: 10.1177\/1759720X12455960 .","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"338_CR52","unstructured":"NCT00988221. A 24\u00a0week randomized, double-blind, placebo-controlled withdrawal trial with a 16\u00a0week open-label lead-in phase, and 64\u00a0week open-label follow-up, to evaluate the effect on clinical response and the safety of tocilizumab in patients with active polyarticular-course juvenile idiopathic arthritis."},{"issue":"10 (Supplement)","key":"338_CR53","first-page":"S682","volume":"64","author":"HI Brunner","year":"2012","unstructured":"Brunner HI, Ruperto N, Zuber Z, Keane K, Harari O, Kenwright A, et al. Efficacy and safety of tocilizumab in patients with polyarticular juvenile idiopathic arthritis: data from a phase 3 trial. Arthritis Rheum. 2012;64(10 (Supplement)):S682.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"338_CR54","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10165-011-0481-0","volume":"22","author":"T Imagawa","year":"2012","unstructured":"Imagawa T, Yokota S, Mori M, Miyamae T, Takei S, Imanaka H, et al. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol. 2012;22(1):109\u201315. doi: 10.1007\/s10165-011-0481-0 .","journal-title":"Mod Rheumatol"},{"issue":"6","key":"338_CR55","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3899\/jrheum.120010","volume":"39","author":"C Tappeiner","year":"2012","unstructured":"\u2022 Tappeiner C, Heinz C, Ganser G, Heiligenhaus A. Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol. 2012;39(6):1294\u20135. doi: 10.3899\/jrheum.120010 . Tocilizumab has been reported off-label for use in JIA associated uveitis (which is not a feature of sJIA) and may become a second-line therapy.","journal-title":"J Rheumatol"},{"key":"338_CR56","unstructured":"NCT01603355. An open-label trial to assess the efficacy and safety of tocilizumab in the management of juvenile idiopathic arthritis associated vision-threatening uveitis that is refractory to other modes of systemic immunosuppression."},{"issue":"2","key":"338_CR57","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.27221","volume":"62","author":"GG Illei","year":"2010","unstructured":"Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62(2):542\u201352. doi: 10.1002\/art.27221 .","journal-title":"Arthritis Rheum"},{"issue":"2","key":"338_CR58","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1365-2125.2011.03964.x","volume":"72","author":"Z Xu","year":"2011","unstructured":"Xu Z, Bouman-Thio E, Comisar C, Frederick B, Van Hartingsveldt B, Marini JC, et al. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol. 2011;72(2):270\u201381. doi: 10.1111\/j.1365-2125.2011.03964.x .","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"338_CR59","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1046\/j.1365-2141.1998.00835.x","volume":"102","author":"HC Zaanen Van","year":"1998","unstructured":"Van Zaanen HC, Lokhorst HM, Aarden LA, Rensink HJ, Warnaar SO, van der Lelie J, et al. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. Br J Haematol. 1998;102(3):783\u201390.","journal-title":"Br J Haematol"},{"issue":"7","key":"338_CR60","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1136\/annrheumdis-2011-200704","volume":"71","author":"P Mease","year":"2012","unstructured":"Mease P, Strand V, Shalamberidze L, Dimic A, Raskina T, Xu LA, et al. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann Rheum Dis. 2012;71(7):1183\u20139. doi: 10.1136\/annrheumdis-2011-200704 .","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"338_CR61","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1002\/art.24750","volume":"60","author":"W Jager De","year":"2009","unstructured":"De Jager W, Vastert SJ, Beekman JM, Wulffraat NM, Kuis W, Coffer PJ, et al. Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2009;60(9):2782\u201393. doi: 10.1002\/art.24750 .","journal-title":"Arthritis Rheum"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-013-0338-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-013-0338-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-013-0338-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T06:57:32Z","timestamp":1715410652000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-013-0338-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,29]]},"references-count":61,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["338"],"URL":"https:\/\/doi.org\/10.1007\/s11926-013-0338-y","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,29]]},"article-number":"338"}}